<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382510</url>
  </required_header>
  <id_info>
    <org_study_id>TRN-157-102</org_study_id>
    <nct_id>NCT02382510</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Two-Way Cross-Over, Phase 2a Study to Evaluate the Safety and Bronchodilator Activity of TRN-157 in Stable Mild and Moderate Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theron Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theron Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This multiple ascending dose study is to determine the safety and bronchodilator activity of
      TRN-157 in 59 mild and moderate asthmatics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in FEV1</measure>
    <time_frame>After 2 weeks of treatment with TRN-157 vs. Placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as determined by number of subjects with adverse events</measure>
    <time_frame>After 2 weeks of treatment with TRN-157 vs. Placebo</time_frame>
    <description>Adverse events and/or clinically significant changes in vital signs, ECG, and/or laboratory values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize effects on pulmonary function</measure>
    <time_frame>After 2 weeks of treatment with TRN-157 vs. Placebo</time_frame>
    <description>FEV1(0-4 h); FVC AUC(0-4 h); FVC(0-4 h); Morning PEFR; Trough (pre-dose) FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize effects on asthma symptomatology</measure>
    <time_frame>During the 2 weeks of treatment with TRN-157 vs. Placebo</time_frame>
    <description>Asthma symptoms, including exacerbations; Number of asthma-control days; Rescue inhaler use; Nocturnal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters: AUC0-t, AUC0-inf, Cmax, tmax, t½, elimination rate constant (kel), volume of distribution at steady state (Vss/F), total plasma clearance (CL/F)</measure>
    <time_frame>After 2 weeks of treatment with TRN-157</time_frame>
    <description>AUC0-t, AUC0-inf, Cmax, tmax, t½, elimination rate constant (kel), volume of distribution at steady state (Vss/F), total plasma clearance (CL/F)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>TRN-157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRN-157</intervention_name>
    <arm_group_label>TRN-157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet the following criteria will be considered eligible to participate in the
        study:

          -  The patient is ≥ 18 and &lt; 70 years of age, and gives informed consent

          -  Clinical diagnosis of mild to moderate asthma of at least 6 months duration and age of
             onset &lt; 50 years

          -  Presently using ICS at moderate doses (equivalent to 200-800 µg of budesonide or
             88-500 µg of fluticasone daily)

          -  ≥ 12% and ≥ 200 mL improvement in FEV1 to 4 puffs albuterol by metered-dose inhaler
             (MDI) at screening visit

          -  Patient is willing to use acceptable form of birth control during trial and for one
             month thereafter

          -  Ability to measure morning (AM) peak expiratory flow (PEF) on schedule using
             electronic peak flow meter (EPFM) and to complete the study diary correctly at least
             70% of the time during the run-in period

          -  After 7 day withdrawal from LABA therapy and overnight withdrawal from SABA therapy
             (except rescue medication), patient has between 55% - 80% of predicted FEV1 at CV2

        Exclusion Criteria:

        A patient meeting any of the following criteria is not eligible for enrollment in the
        study:

          -  A clinical diagnosis of chronic obstructive pulmonary disease (COPD), chronic
             bronchitis, bronchiectasis, or other significant pulmonary disease other than asthma

          -  History of upper or lower respiratory infection within 4 weeks of screening

          -  History of asthma exacerbation requiring oral or systemic corticosteroids or hospital
             admission within 6 months of screening

          -  History of myocardial infarction, or cardiac conduction abnormalities, including but
             not limited to atrial fibrillation, and paroxysmal atrial tachycardia

          -  Hospitalization due to cardiac failure within the last 6 months

          -  History of narrow angle glaucoma or obstructive uropathy

          -  Current smokers or vapers, or former smokers with &gt; 10 pack-year (self-reported)
             history of smoking

          -  Patients who presently use the following medications will not be eligible for
             participation:

               -  Long-acting muscarinic receptor antagonist (LAMA)

               -  LABA (but may be withdrawn and converted to SABA x 7 days prior to entry)

               -  Leukotriene pathway blockers

               -  Anti-IgE antibody (Xolair) within last 6 months prior to CV1

               -  Phosphodiesterase 4 (PDE4) inhibitors (e.g., Roflumilast)

               -  Cromolyn

               -  Methylxanthines (e.g., aminophylline and theophylline)

               -  5-Lipoxygenase inhibitor (e.g., Zileuton)

          -  Allergies to LAMA therapies

          -  History of life-threatening asthma exacerbation requiring ICU admission, mechanical
             ventilation, or tracheostomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Krantz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Theron Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Research</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Research</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Winder &amp; Associates/Toledo Center for Clinical Research</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Allergy and Asthma Center of Southern Oregon</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <disposition_first_submitted>May 5, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 8, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 9, 2017</disposition_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

